FDA Approves BV+R2 Combo for R/R LBCL ...Middle East

Medscape - News
FDA Approves BV+R2 Combo for R/R LBCL
Adding brentuximab vedotin to lenalidomide and rituximab significantly reduced the risk for death by 37% in the randomized, placebo-controlled ECHELON-3 trial. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves BV+R2 Combo for R/R LBCL )

Also on site :



Latest News